Allianz Asset Management AG maintained its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) during the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,074 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Allianz Asset Management AG’s holdings in Agios Pharmaceuticals were worth $462,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in AGIO. First Mercantile Trust Co. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $137,000. Beech Hill Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $217,000. Parametrica Management Ltd purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $246,000. OMERS ADMINISTRATION Corp boosted its stake in shares of Agios Pharmaceuticals by 8.0% in the third quarter. OMERS ADMINISTRATION Corp now owns 5,400 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 400 shares during the period. Finally, Utah Retirement Systems boosted its stake in shares of Agios Pharmaceuticals by 7.8% in the third quarter. Utah Retirement Systems now owns 5,500 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 88.79% of the company’s stock.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) traded down 2.67% during mid-day trading on Friday, reaching $46.99. The company’s stock had a trading volume of 730,085 shares. The company’s 50-day moving average price is $53.47 and its 200 day moving average price is $50.50. The firm’s market capitalization is $1.98 billion. Agios Pharmaceuticals Inc has a 52 week low of $35.84 and a 52 week high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.51) by $0.17. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The company had revenue of $22.65 million for the quarter, compared to the consensus estimate of $10.89 million. During the same period last year, the firm posted ($1.08) EPS. The company’s revenue for the quarter was up 264.5% on a year-over-year basis. On average, equities analysts forecast that Agios Pharmaceuticals Inc will post ($7.31) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Allianz Asset Management AG Maintains Stake in Agios Pharmaceuticals Inc (AGIO)” was published by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://baseballnewssource.com/markets/agios-pharmaceuticals-inc-agio-stake-maintained-by-allianz-asset-management-ag-updated-updated/525709.html.
Several brokerages have weighed in on AGIO. Cann reissued a “buy” rating and set a $75.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday. Oppenheimer Holdings Inc. raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a research note on Tuesday, January 17th. Cowen and Company restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, February 16th. Janney Montgomery Scott upgraded Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $57.00 target price for the company in a research report on Thursday, February 16th. Finally, Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, February 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $63.49.
In other news, Director Lewis Clayton Jr. Cantley sold 5,090 shares of the firm’s stock in a transaction dated Tuesday, April 18th. The shares were sold at an average price of $54.37, for a total value of $276,743.30. Following the transaction, the director now directly owns 93,751 shares in the company, valued at approximately $5,097,241.87. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Scott Biller sold 6,438 shares of the stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $55.00, for a total transaction of $354,090.00. Following the completion of the sale, the insider now directly owns 21,403 shares in the company, valued at approximately $1,177,165. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 445,791 shares of company stock worth $22,197,388. Insiders own 10.55% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with our FREE daily email newsletter.